Linaclotide 145 μg (IBS-C Participants) for Constipation

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Children's Ctr Digestive, US /ID# 233070, Atlanta, GAConstipation+1 MoreLinaclotide 145 μg (IBS-C Participants) - Drug
Eligibility
6 - 17
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a drug called linaclotide to see if it is safe and effective in treating children with constipation or irritable bowel syndrome.

Eligible Conditions
  • Constipation
  • Constipation-predominant Irritable Bowel Syndrome (IBS-C)

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

2 Primary · 6 Secondary · Reporting Duration: 12 Weeks

12 Weeks
Functional Constipation (FC) Participants: Change from baseline in 12-week SBM (spontaneous bowel movement) frequency rate (SBMs/week) during the study intervention period
Functional Constipation (FC) Participants: Change from baseline in 12-week stool consistency during the study intervention period
Irritable Bowel Syndrome with Constipation (IBS-C) Participants: 6/12 weeks APS (abdominal pain and SBM) + 2 responder
Irritable Bowel Syndrome with Constipation (IBS-C) Participants: 6/12 weeks SBM + 2 responder
Irritable Bowel Syndrome with Constipation (IBS-C) Participants: 6/12 weeks abdominal pain responder
Irritable Bowel Syndrome with Constipation (IBS-C) Participants: Change from baseline in 12-week SBM frequency rate (SBMs/week) during the study intervention period
Irritable Bowel Syndrome with Constipation (IBS-C) Participants: Change from baseline in 12-week abdominal pain during the study intervention period
Irritable Bowel Syndrome with Constipation (IBS-C) Participants: Change from baseline in 12-week stool consistency during the study intervention period

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

4 Treatment Groups

Placebo
1 of 4
Linaclotide 72 μg
1 of 4
Linaclotide 290 μg
1 of 4
Linaclotide 145 μg
1 of 4

Experimental Treatment

426 Total Participants · 4 Treatment Groups

Primary Treatment: Linaclotide 145 μg (IBS-C Participants) · Has Placebo Group · Phase 3

Placebo
Drug
Experimental Group · 1 Intervention: Placebo (FC Participants) · Intervention Types: Drug
Linaclotide 72 μg
Drug
Experimental Group · 1 Intervention: Linaclotide 72 μg (FC Participants) · Intervention Types: Drug
Linaclotide 290 μg
Drug
Experimental Group · 1 Intervention: Linaclotide 290 μg (IBS-C Participants) · Intervention Types: Drug
Linaclotide 145 μg
Drug
Experimental Group · 1 Intervention: Linaclotide 145 μg (IBS-C Participants) · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 12 weeks

Who is running the clinical trial?

AllerganLead Sponsor
781 Previous Clinical Trials
276,089 Total Patients Enrolled
2 Trials studying Constipation
155 Patients Enrolled for Constipation
Ironwood Pharmaceuticals, Inc.Industry Sponsor
40 Previous Clinical Trials
16,510 Total Patients Enrolled
25 Trials studying Constipation
13,482 Patients Enrolled for Constipation
ALLERGAN INC.Study DirectorAllergan
73 Previous Clinical Trials
78,273 Total Patients Enrolled
1 Trials studying Constipation
120 Patients Enrolled for Constipation

Eligibility Criteria

Age 6 - 17 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have experienced a change in your bowel movement frequency.
You must stop using your usual laxatives during the study and use only the medication provided by the study team if needed.
You have less than three bowel movements per week without using any medication to help you go.
You must be between 6 and 17 years old (for FC participants) or between 7 and 17 years old (for IBS-C participants) when you agree to participate in the study. Your parent or legal guardian must also sign a consent form.
You weigh at least 18 kilograms when you and your parent or guardian agree to participate in the study.
You have a history of holding in bowel movements, having painful or large bowel movements, or experiencing fecal incontinence at least once a week. You may also have a large mass of stool in your rectum that could cause toilet blockages.
You have noticed a change in the shape or appearance of your stool.
You have difficulty going to the bathroom and have less than 2 bowel movements per week without taking any medication to help you go.
If you have constipation-predominant irritable bowel syndrome (IBS-C), you must have had at least "a tiny bit" of abdominal pain during the daytime on most days for the two weeks before Visit 3.
Feeling better after having a bowel movement.

Who else is applying?

What state do they live in?
Georgia50.0%
California50.0%
How old are they?
18 - 65100.0%
What site did they apply to?
Medical Ctr for Clin Research /ID# 23300450.0%
Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 23294050.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%

Frequently Asked Questions

Are people still being accepted into the program?

"This study, as indicated by clinicaltrials.gov, is still recruiting patients. The trial was originally advertised on October 1st 2019 with the most recent update being November 9th 2022." - Anonymous Online Contributor

Unverified Answer

What other tests involving Linaclotide 145 μg have been done with patients who suffer from IBS-C?

"Linaclotide 145 μg (IBS-C Participants) was first studied in 2015 at Texas Tech University Health Sciences Center. To date, a total of 27 studies have been completed, with 3 more trials currently underway. Many of these trials are based out of Plano, Texas." - Anonymous Online Contributor

Unverified Answer

What is the focus of this research?

"The main objective of this study is to assess the effectiveness of a new medication for treating Irritable Bowel Syndrome with Constipation (IBS-C). The study will last for 12 weeks, and participants will be asked to keep track of their bowel movements using an electronic diary. Secondary objectives include measuring changes in stool consistency and frequency of bowel movements over the course of the study." - Anonymous Online Contributor

Unverified Answer

Could I join the ranks of this clinical trial?

"This clinical trial is seeking 426 patients aged 6-17 that suffer from irritable bowel syndrome. The criteria for applicants are as follows: The child must be of the appropriate age range, have a body weight of at least 18kg, meet the Rome III criteria for FC, have experienced no more than 2 defecations per week, show improvement with defecation, and be willing to discontinue use of laxatives. For IBS-C participants specifically, they must also have an average daytime abdominal pain score of 1 or higher." - Anonymous Online Contributor

Unverified Answer

Are there any dangers associated with Linaclotide 145 μg (IBS-C Participants)?

"The safety of Linaclotide 145 μg has been well documented in prior Phase 3 trials, and it thus receives a score of 3." - Anonymous Online Contributor

Unverified Answer

Are there any participating hospitals in North America?

"This study is running at AIM Trials /ID# 232934 in Plano, Texas, David M. Headley, MD, P.A. /ID# 233153 in Port Gibson, Mississippi, and GI associates and Endoscopy Ce /ID# 233123 in Flowood, Oklahoma as well as other sites 73 other locations." - Anonymous Online Contributor

Unverified Answer

How many patients have signed up to participate in this clinical trial?

"Yes, the trial is ongoing and recruiting patients. According to clinicaltrials.gov, this study was first posted on October 1st, 2019 and was last updated November 9th, 2020. They are looking for 426 participants at 73 different sites." - Anonymous Online Contributor

Unverified Answer

Does this research opportunity extend to young adults?

"According to the inclusion criteria, participants must be between 6 and 17 years old." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.